Rubius Therapeutics Probability of Future Pink Sheet Price Finishing Over 0.0789
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
Rubius |
Rubius Therapeutics Target Price Odds to finish over 0.0789
The tendency of Rubius Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 0.08 in 90 days |
| 0.08 | 90 days | 0.08 | about 99.0 |
Based on a normal probability distribution, the odds of Rubius Therapeutics to stay above $ 0.08 in 90 days from now is about 99.0 (This Rubius Therapeutics probability density function shows the probability of Rubius Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Rubius Therapeutics price to stay between $ 0.08 and its current price of $0.083 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 1.73 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Rubius Therapeutics will likely underperform. Additionally Rubius Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Rubius Therapeutics Price Density |
| Price |
Predictive Modules for Rubius Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rubius Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Rubius Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Rubius Therapeutics is not an exception. The market had few large corrections towards the Rubius Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Rubius Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Rubius Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.77 | |
β | Beta against Dow Jones | 1.73 | |
σ | Overall volatility | 0.05 | |
Ir | Information ratio | -0.05 |
Rubius Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rubius Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rubius Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Rubius Therapeutics is not yet fully synchronised with the market data | |
| Rubius Therapeutics has some characteristics of a very speculative penny stock | |
| Rubius Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (179.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rubius Therapeutics currently holds about 140.71 M in cash with (150.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are owned by institutional investors |
Rubius Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Rubius Pink Sheet often depends not only on the future outlook of the current and potential Rubius Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rubius Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 90.4 M |
Rubius Therapeutics Technical Analysis
Rubius Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Rubius Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Rubius Therapeutics. In general, you should focus on analyzing Rubius Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Rubius Therapeutics Predictive Forecast Models
Rubius Therapeutics' time-series forecasting models is one of many Rubius Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Rubius Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Rubius Therapeutics
Checking the ongoing alerts about Rubius Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Rubius Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Rubius Therapeutics is not yet fully synchronised with the market data | |
| Rubius Therapeutics has some characteristics of a very speculative penny stock | |
| Rubius Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (179.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rubius Therapeutics currently holds about 140.71 M in cash with (150.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are owned by institutional investors |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |